# Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)

> **NCT00535743** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 174 (actual)

## Conditions studied

- Anesthesia, General

## Interventions

- **DRUG:** Sugammadex
- **DRUG:** Placebo
- **DRUG:** Esmeron®

## Key facts

- **NCT ID:** NCT00535743
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03-04
- **Primary completion:** 2004-07-20
- **Final completion:** 2004-07-20
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2019-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00535743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00535743, "Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00535743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*